NEW YORK (GenomeWeb) – MolecularMD has partnered with Asterand Bioscience to provide its biopharma customers with an end-to-end workflow for biomarker and cancer drug target validation, and assay development, the companies announced today.

Under the terms of the deal, MolecularMD will access Asterand's human tissue procurement, characterization, and research services to assist with the development of custom clinical trial assays and companion diagnostic products for its clients. Specific details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.